Local Treatment Guidelines Non-Small Cell Lung Cancer (FOI)Local Treatment Guidelines Non-Small Cell Lung Cancer (FOI)
Produced by the Freedom of Information officeAuthored by Government of Jersey and published on
13 January 2023.Prepared internally, no external costs.
Request
Local Treatment Guidelines Non-Small Cell Lung Cancer
A
Does States of Jersey Health and Social Services have any local treatment guidelines, pathways, protocols or algorithms for the treatment of non-small cell lung cancer? If yes please provide a copy.
B
Does States of Jersey Health and Social Services have protocols for the use of the targeted drug therapies in the treatment of non-small cell lung cancer in the attached list?
Drug therapies list.pdf
C
If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?
D
Does States of Jersey Health and Social Services have any local pathways, protocols, or guidelines for the use of molecular biomarker testing in diagnosis and treatment of non-small cell lung cancer? If yes please provide a copy.
E
Is States of Jersey Health and Social Services part of a Cancer alliance or network, if so which ones?
Response
A
The Government of Jersey Health and Community Services (HCS) department use NICE pathways and algorithms for the treatment of non-small cell lung cancer. There is no local individual drug protocol. HCS follow the protocols from University Hospital Southampton.
B
As per the response to question A, HCS follow the protocols from University Hospital Southampton. HCS’ lead clinician for lung cancer has confirmed the following targeted drug therapies have been used in their treatment of patients with non-small cell lung cancer, as appropriate to the patient:
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Afatinib (Giotrif)
- Erlotinib (Tarceva)
- Gefitinib (Iressa)
- Osimertinib (Tagrisso)
- Alectinib (Alecensa)
- Ceritinib (Zykadia)
- Crizotinib (Xalkori)
- Lorlatinib (Lorviqua )
- Nintedanib (Vargatef®)
Other drugs from the list provided for question B will be used for patients where appropriate in due course.
C
Not applicable.
D
HCS use University Hospital Birmingham for molecular biomarker testing, including EGFR, ALK, PDL-1, ROS-1, KRAS, HER 2, BRAF, as appropriate.
E
HCS is not part of a specific cancer alliance or network, but utilise the service for non-small cell lung cancer from Birmingham.
gov.je